FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ward, E. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ward, E. S.

The FASEB Journal, Vol 6, 2422-2427, Copyright © 1992 by The Federation of American Societies for Experimental Biology

REVIEWS

Antibody engineering: the use of Escherichia coli as an expression host

ES Ward
Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas 75235-9048.

The hypervariable loops of an antibody molecule are supported on the relatively conserved beta-sheeted frameworks of the heavy- and light- chain variable domains (designated VH and VL domains, respectively). Residues within and flanking these loops interact with antigen and confer the specificity and affinity of antigen binding on the immunoglobulin molecule. Thus, the isolation and expression of VH and VL domain genes are of particular interest both for analysis of the determinants of antibody specificity and for generation of fragments with binding affinities for use in therapy and diagnosis. The PCR can now be used to isolate diverse repertoires of antibody VH and VL domain genes from antibody-producing cells from different species, including humans and mice. The genes can be expressed as either secreted or surface-bound Fv or Fab fragments, using Escherichia coli expression systems, and the desired antigen-binding specificity screened for or, preferably, selected. The use of E. coli as an expression host allows the required antigen-binding specificity to be isolated in clonal form in a matter of days. The VH and VL domain genes can also be hypermutated and higher-affinity variants isolated by screening or selection. Thus, the use of this technology should allow the isolation of novel binding specificities or specificities that are difficult to generate by hybridoma technology. It will also facilitate the isolation of human-derived Fv/Fab fragments that may be less immunogenic in therapy. This approach therefore has almost unlimited potential in the generation of therapeutics with binding specificities to order. The fragments can be used either alone or linked to effector functions in the form of antibody-constant domains or toxins. The new technology could prove to be a method of choice for the rapid and convenient production of designer antibodies.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Sano, S. Vajda, C. L. Smith, and C. R. Cantor
Engineering subunit association of multisubunit proteins: A dimeric streptavidin
PNAS, June 10, 1997; 94(12): 6153 - 6158.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Forsberg, M. Forsgren, M. Jaki, M. Norin, C. Sterky, A. Enhorning, K. Larsson, M. Ericsson, and P. Bjork
Identification of Framework Residues in a Secreted Recombinant Antibody Fragment That Control Production Level and Localization in Escherichia coli
J. Biol. Chem., May 9, 1997; 272(19): 12430 - 12436.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
M.G. Emara, S.R.C. Malburg, and J.S. Lam
Expression of an anti-Pseudomonas aeruginosa lipopolysaccharide core recombinant antibody in Escherichia coli
Innate Immunity, February 1, 1995; 2(1): 53 - 61.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The Federation of American Societies for Experimental Biology.